Current health news highlights include Novo Nordisk's Alzheimer's trials with GLP-1s, Agilent's strong revenue driven by lab ...

Data from the Evoke trials suggests that GLP-1 drugs that treat type 2 diabetes do not have a significant effect on Alzheimer ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Discover why Novo Nordisk’s stagnating growth and lower obesity drug efficacy may signal more downside risk for investors.

Novo Nordisk shares rose 5% on Wednesday after analysts said that U.S. price cuts for the Danish drugmaker's semaglutide came in broadly as expected.

Major stock indexes ended sharply higher Monday to begin a holiday-shortened trading week, with investors increasingly confident the Federal Reserve will cut interest rates at its December meeting.

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.

Today’s Forbes Daily newsletter covers Amazon’s latest AI investment, Novo Nordisk’s tough Ozempic test, SoftBank stumbles, ...

Novo Nordisk A/S remains a Strong Buy despite semaglutide's Alzheimer's trial miss. Click for NVO growth drivers, solid ...